4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Pain by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 5192 ongoing clinical trials involving Pain
Of the 5192 trials,2066 trials are in Phase II
Furthermore, 1268 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Pain by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Pain, a central nervous system condition. The largest number of ongoing clinical trials for Pain is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Pain-related drug trials.

Assiut University: The leading ongoing Pain related clinical trial sponsor

Assiut University is the top sponsor for Pain-related ongoing clinical trials.

Cairo University, West China Hospital of Sichuan University, Mansoura University, and Isfahan University of Medical Sciences are among other notable clinical trial sponsors involved in Pain. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Pain

Varicella zoster vaccine (Shingrix/GSK-1437173A), Onabotulinumtoxin A (Botox), and Metoprolol succinate (Toprol XL, Zarmine, Beloken, Seloken, Metoprodur, Selozok, Betaloc CR, Betaloc Zok, Agoloc, Belok Zok,) are among the key marketed drugs involving Pain.

Varicella zoster vaccine (Shingrix/GSK-1437173A) is a sterile, non-live vaccine of recombinant varicella zoster virus surface glycoprotein E (VZV gE) produced in Chinese Hamster Ovarian (CHO) cells by recombinant DNA technology. It is adjuvanted with AS01B containing plant extract Quillaja saponaria Molina, fraction 21 (QS-21), a liposomal formulation and acts as an immuno protective agent. It is formulated as injectable lyophilized powder for suspension, for intramuscular route of administration. Shingrix is indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older and adults 18 years of age and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy. Varicella zoster vaccine was first approved in 2017 and is marketed globally including the US, France, Germany, and Japan by GlaxoSmithKline Plc.

Onabotulinumtoxin A (Botox) is a sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strain Clostridium botulinum type A. It functions via Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor mechanism of action. It is formulated as injectable powder solution for intramuscular, subcutaneous and intradermal route of administration. Botox is indicated for the treatment of pain and several other indications including Migraine, Dystonia, Cerebral Palsy, Overactive Bladder, Neurogenic Bladder Dysfunction, Urinary Incontinence, Axillary Hyperhidrosis, Blepharospasm, Hemifacial Spasm, Lower Limb Muscle Spasticity, Muscle Spasm, Muscle Spasticity, and Paralytic Strabismus. Botox was first approved in 1991 and is marketed globally including the US, France, Germany, and Japan by several pharma giants including AbbVie Inc and Allergan Sales LLC.